Xiu Luo
No. 415, Fengyang Road
Huangpu, China
Huangpu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.
Journal: Frontiers in immunology
Published: April 23, 2026
Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL.
Journal: Experimental hematology & oncology
Published: April 03, 2026
68Ga-FAPI-04 PET/CT for the early diagnosis of multi-organ fibrosis and functional impairments caused by platinum-based chemotherapy.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 08, 2025
The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma.
Journal: iScience
Published: October 09, 2025
Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.
Journal: Journal of translational medicine
Published: September 02, 2025
Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers.
Journal: The Journal of biological chemistry
Published: May 09, 2025
Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes.
Journal: Seminars in oncology
Published: April 15, 2025
Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study.
Journal: Frontiers in immunology
Published: February 25, 2025
CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma.
Journal: Current research in translational medicine
Published: October 17, 2024
Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies.
Journal: Chinese medical journal
Published: July 18, 2024
An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk.
Journal: Chinese medical journal
Published: May 27, 2024
Last Updated: 09/26/2026